Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members

Matulay, Justin T.; Tabayoyong, William; Duplisea, Jonathan J.; Chang, Courtney M.; Daneshmand, Siamak; Gore, John L.; Holzbeierlein, Jeffrey M.; Karsh, Lawrence I.; Kim, Simon P.; Konety, Badrinath R.; Li, Roger; McKiernan, James M.; Messing, Edward M.; Steinberg, Gary D.; Williams, Stephen B.; Kamat, Ashish M.

doi:10.1016/j.urolonc.2020.04.026

Cited by 15 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,21 However, consistent with the findings of the present study, practitioner-reported adherence to guidelines among low-risk patients remains low. 8 Our study had several notable findings. First, to our knowledge, this study performed one of the largest population-based analyses of surveillance patterns among patients with low-grade Ta NMIBC.…”

Section: Discussionmentioning

confidence: 62%

Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013

et al. 2022

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Low-risk non-muscle-invasive bladder cancer (NMIBC) is associated with extremely low rates of progression and cancer-specific mortality; however, patients with low-risk NMIBC may often receive non-guideline-recommended and potentially costly surveillance testing and treatment. OBJECTIVE To describe current surveillance and treatment practices, cancer outcomes, and costs of care for low-grade papillary stage Ta (low-grade Ta) NMIBC and identify factors associated with increased cost of care. DESIGN, SETTING, AND PARTICIPANTS This population-based cohort study identified 13 054 older adults (aged 66-90 years) diagnosed with low-grade Ta tumors in the Surveillance,

show abstract

Section: Discussionmentioning

confidence: 62%

Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, a study [ 13 ] by members of the Society of Urologic Oncologists (SUO) found that cystoscopy and cytology are overused among low-risk patients.…”

Section: Introduction: Bladder Cancer Issues and Urinary Biomarkersmentioning

confidence: 99%

A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers

Matuszczak

Kiljańczyk

Salagierski

2022

IJMS

View full text Add to dashboard Cite

The non-muscle invasive bladder cancer tends to recur and progress. Therefore, it requires frequent follow-ups, generating costs and making it one of the most expensive neoplasms. Considering the expensive and invasive character of the current gold-standard diagnostic procedure, white-light cystoscopy, efforts to find an alternative method are ongoing. Although the last decade has seen significant advancements in urinary biomarker tests (UBTs) for bladder cancer, international guidelines have not recommended them. Currently, the paramount urgency is to find and validate the test with the best specificity and sensitivity, which would allow for the optimizing of diagnosis, prognosis, and a treatment plan. This review aims to summarise the up-to-date state of knowledge relating to UBTs and new developments in the detection, prognosis, and surveillance of bladder cancer and their potential applications in clinical practice.

show abstract

“…Our recent work as well as the work of others has shown that despite guideline recommendations, risk-aligned surveillance does not regularly occur. [2][3][4][5][6] We used nonmuscle-invasive bladder cancer within the Department of Veterans Affairs (VA)-where it is the third most prevalent noncutaneous cancer 7 -as an important model to study risk-aligned surveillance. The most common risk these patients face is recurrence within the bladder.…”

Section: Introductionmentioning

confidence: 99%

Determinants of Risk-Aligned Bladder Cancer Surveillance—Mixed-Methods Evaluation Using the Tailored Implementation for Chronic Diseases Framework

Schroeck

Ismail

Perry

et al. 2022

JCO Oncology Practice

View full text Add to dashboard Cite

PURPOSE: For many patients with cancer, the frequency of surveillance after primary treatment depends on the risk for cancer recurrence or progression. Lack of risk-aligned surveillance means too many unnecessary surveillance procedures for low-risk patients and not enough for high-risk patients. Using bladder cancer as an example, we examined whether practice determinants differ between Department of Veterans Affairs sites where risk-aligned surveillance was more (risk-aligned sites) or less common (need improvement sites). METHODS: We used our prior quantitative data to identify two risk-aligned sites and four need improvement sites. We performed semistructured interviews with 40 Veterans Affairs staff guided by the Tailored Implementation for Chronic Diseases framework that were deductively coded. We integrated quantitative data (risk-aligned site v need improvement site) and qualitative data from interviews, cross-tabulating salient determinants by site type. RESULTS: There were 14 participants from risk-aligned sites and 26 participants from need improvement sites. Irrespective of site type, we found a lack of knowledge on guideline recommendations. Additional salient determinants at need improvement sites were a lack of resources (“the next available without overbooking is probably seven to eight weeks out”) and an absence of routines to incorporate risk-aligned surveillance (“I have my own guidelines that I've been using for 35 years”). CONCLUSION: Knowledge, resources, and lack of routines were salient barriers to risk-aligned bladder cancer surveillance. Implementation strategies addressing knowledge and resources can likely contribute to more risk-aligned surveillance. In addition, reminders for providers to incorporate risk into their surveillance plans may improve their routines.

show abstract

Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members

Cited by 15 publications

References 21 publications

Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013

Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013

A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers

Determinants of Risk-Aligned Bladder Cancer Surveillance—Mixed-Methods Evaluation Using the Tailored Implementation for Chronic Diseases Framework

Contact Info

Product

Resources

About